AstraZeneca Inks R&D Deal With Ramaswamy's Roivant for Hush-Hush Indication Post author:Sam Post published:October 18, 2017 Post category:BioPharma Vivek Ramaswamy’s parent company, Roivant Sciences, inked a development deal with Astra. Source: BioSpace You Might Also Like Cytokinetics Scraps Lead ALS Drug After Late-Stage Trial Failure November 20, 2017 Juno Therapeutics Spinout Raises $90M March 7, 2018 Biotech Execs are Hoping Will Pick This Man to Head the FDA February 5, 2017
